BCG, the only vaccine licensed against tuberculosis, demonstrates variable efficacy in
humans. Recent preclinical studies highlight the potential for mucosal BCG vaccination to
improve protection. Lung tissue-resident memory T cells reside within the parenchyma,
potentially playing an important role in protective immunity to tuberculosis. We hypothesised
that mucosal BCG vaccination may enhance generation of lung tissue-resident T cells,
affording improved protection against Mycobacterium tuberculosis. In a mouse model …